(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Reclassifying Achievement: Individual Accounts of Seeking after Interests- Nitty gritty Manual for Picking Agreeable Tennis shoes
- Vote In favor of Your Favored Kind Of Cheddar
- The Most Vital Crossroads in Olympic History
- The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life
- 21 Incredibly Interesting Contemplations To Observe Consistently
- Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
